A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer
Phase of Trial: Phase I/II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Olaparib (Primary) ; Tremelimumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2020.
- 06 Jun 2017 Preliminary results (n=3) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 24 Feb 2016 Planned End Date changed from 1 Mar 2022 to 1 Feb 2022 as reported by ClinicalTrials.gov.